What is the 13F Pro Quality Score for TLSI?

13F Pro ranks TriSalus Life Sciences, Inc. (TLSI) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View TLSI's current score at https://13fpro.ai/research/TLSI (free sign-up required for the full ranking).

Where does 13F Pro source TLSI data?

All TriSalus Life Sciences, Inc. fundamentals and ownership data come directly from SEC EDGAR. TriSalus Life Sciences, Inc. files with the SEC under CIK 1826667. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is TLSI in?

TriSalus Life Sciences, Inc. (TLSI) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is TLSI research updated on 13F Pro?

TLSI's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

TriSalus Life Sciences, Inc.(TLSI)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1826667 TLSI stock profile & AI dashboard →

13F Pro Quality Score

28.3/100

Rank #2,443 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

84.4/100

Profitability

8.9/100

Balance Sheet

1.3/100

Earnings Quality

30.0/100

Free Cash Flow

8.7/100

Institutional Flow

94.6/100

Revenue Scale

9.5/100

Dilution Risk

9.1/100

TLSI Stock Analysis & AI Quality Score

AI stock analysis and institutional research for TriSalus Life Sciences, Inc. (TLSI), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores TLSI at 28.3/100 on a 32-signal composite quality model, placing it at rank #2,443 of 2,879 stocks — the bottom half of the AI-ranked universe. TLSI scores in the top quartile across institutional flow (94.6), revenue growth (84.4). Areas of concern include balance sheet strength (1.3) and free cash flow (8.7), which score below median versus the broader universe. Shareholder dilution risk is elevated at 9.1/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), TriSalus Life Sciences, Inc. reports quarterly revenue of $8.9M, net income of $1.5M, free cash flow of $-6.6M. Top institutional holders of TLSI by reported 13-F value include First Light Asset Management,, AWM Investment Company,, Nantahala Capital Management,, based on the most recent SEC filings. TLSI trades on the Nasdaq exchange and files with the SEC under CIK 1826667. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TLSI daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for TriSalus Life Sciences, Inc. directly from SEC EDGAR. TriSalus Life Sciences, Inc.'s 13F Pro composite quality score has ranged between 27 and 30 since 2025, currently 28.3 — a stable long-term trajectory across 11 quarterly and live scoring snapshots.

✦

Fun facts about TriSalus Life Sciences, Inc.

Quirks, history, and lore behind TLSI — the kind of stuff that makes a stock memorable.

1
The Basics
A small-cap U.S. medical device company listed on Nasdaq, focused on improving drug delivery to difficult-to-reach tumors.
2
The Numbers
Revenue is in the low tens of millions of dollars annually — this is a commercial-stage company still working toward profitability, not a household name on Wall Street.
3
The History
The company's technology traces back to work on pressure-enabled drug delivery, aiming to solve a problem oncologists have wrestled with for decades: getting chemotherapy past vascular barriers in tumors.
4
The Secret
Its flagship platform uses increased pressure to push drugs deeper into tumor tissue — a technique called Pressure-Enabled Drug Delivery (PEDD) that standard IV infusion simply can't replicate.
5
The Lore
Its lead device is designed specifically for liver and pancreatic cancers — some of the deadliest and hardest-to-treat malignancies — giving it a niche that larger medtech giants have largely ignored.
6
The Giveaway
The TriNav Infusion System, a pressure-enabled catheter for hepatic artery infusion, is the centerpiece of a Colorado company whose very name hints at three vessels and a life-saving mission.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$8.9M

Net Income

Q1 2026

$1.5M

Free Cash Flow

Q1 2026

$-6.6M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+59.0% YoY

$29.4MFY 2024

FY21 —FY22 $12.4MFY23 $18.5MFY24 $29.4M

Net Income

+49.4% YoY

$-30.0MFY 2024

FY21 $4.8MFY22 $-47.2MFY23 $-59.4MFY24 $-30.0M

Operating Income

+33.6% YoY

$-36.2MFY 2024

FY21 $-3.0MFY22 $-36.4MFY23 $-54.5MFY24 $-36.2M

EPS (Diluted)

+80.6% YoY

$-1.31FY 2024

FY21 —FY22 $-161.55FY23 $-6.77FY24 $-1.31

Total Assets

-2.5% YoY

$24.0MFY 2024

FY21 $250.5MFY22 $22.0MFY23 $24.6MFY24 $24.0M

Total Debt

$22.1MFY 2024

FY21 —FY22 —FY23 $0.00FY24 $22.1M

Op. Cash Flow

+19.2% YoY

$-40.8MFY 2024

FY21 $-1.7MFY22 $-32.3MFY23 $-50.6MFY24 $-40.8M

Metric	FY 2024	FY 2023	FY 2022	FY 2021
Revenue	$29.4M +59.0%	$18.5M +49.3%	$12.4M	—
Net Income	$-30.0M +49.4%	$-59.4M -25.8%	$-47.2M -1089.8%	$4.8M
Operating Income	$-36.2M +33.6%	$-54.5M -49.5%	$-36.4M -1098.4%	$-3.0M
EPS (Diluted)	$-1.31 +80.6%	$-6.77 +95.8%	$-161.55	—
Total Assets	$24.0M -2.5%	$24.6M +11.8%	$22.0M -91.2%	$250.5M
Total Debt	$22.1M	$0.00	—	—
Operating Cash Flow	$-40.8M +19.2%	$-50.6M -56.5%	$-32.3M -1759.1%	$-1.7M

AI Insight: TLSI Financial Trends

TriSalus swung to Q1 2026 profitability on stabilizing revenue, but operating losses persist and balance sheet leverage remains elevated.

• Net income turned positive at $2M in Q1 2026, reversing $10M loss in Q4 2025; first profitable quarter in dataset.

• Revenue grew 86% from Q2 2024 ($7M) to Q4 2025 ($13M), though Q1 2026 revenue fell 31% to $9M sequentially.

• Operating cash burn improved sharply: Q1 2026 outflow of $6M versus $13M in Q2 2024, indicating spending control.

⚠ Operating income remains deeply negative ($8M loss in Q1 2026) despite gross profitability, signaling high structural costs.

⚠ Q1 2026 revenue collapse (31% QoQ) contradicts prior growth trajectory; sustainability unclear.

⚠ Debt constant at $33M since Q1 2025 while equity swung from $34M negative to $13M positive; deleveraging stalled.

AI Insight: TLSI Ratio Trends

Q1 2026 swung to net profitability after nine consecutive quarters of losses, but operating margin collapsed and ROIC deteriorated sharply.

• Net profit margin reached 17.3% in Q1 2026 vs. -73.9% in Q3 2025, signaling first profitable quarter since Q2 2024.

• Operating margin fell to -94.5% in Q1 2026 from -24.8% in Q4 2025, worst in trailing 18 months despite net profitability.

• ROIC declined to -73.3% in Q1 2026; D/E ratio unchanged at 2.58, indicating elevated leverage persists.

⚠ Profitability driven by non-operating gains rather than core operations; operating margin remains deeply negative.

⚠ Return metrics (ROE 48.1%, ROA 8.7%) spike in Q1 2026 but likely reflect annualization of one-off quarterly results.

Get alerted when TLSI's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for TriSalus Life Sciences, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of TLSI

First Light Asset Management, LLC
$20.3M5,066,827 sh
AWM Investment Company, Inc.
$8.3M2,079,105 sh
Nantahala Capital Management, LLC
$8.3M2,070,827 sh
BlackRock, Inc.
$6.0M1,499,547 sh
WASATCH ADVISORS LP
$5.8M1,437,960 sh
VANGUARD CAPITAL MANAGEMENT LLC
$5.4M1,347,036 sh
GILDER GAGNON HOWE & CO LLC
$3.6M888,515 sh
Cerity Partners LLC
$3.1M787,272 sh
GEODE CAPITAL MANAGEMENT, LLC
$3.1M777,094 sh
KENNEDY CAPITAL MANAGEMENT LLC
$1.9M485,242 sh

Fund	Value	Shares
First Light Asset Management, LLC	$20.3M	5,066,827
AWM Investment Company, Inc.	$8.3M	2,079,105
Nantahala Capital Management, LLC	$8.3M	2,070,827
BlackRock, Inc.	$6.0M	1,499,547
WASATCH ADVISORS LP	$5.8M	1,437,960
VANGUARD CAPITAL MANAGEMENT LLC	$5.4M	1,347,036
GILDER GAGNON HOWE & CO LLC	$3.6M	888,515
Cerity Partners LLC	$3.1M	787,272
GEODE CAPITAL MANAGEMENT, LLC	$3.1M	777,094
KENNEDY CAPITAL MANAGEMENT LLC	$1.9M	485,242

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put TLSI on your watchlist

Track score changes the day TriSalus Life Sciences, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is TLSI a good stock to buy?

13F Pro's AI-powered analysis of TriSalus Life Sciences, Inc. (TLSI) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for TLSI are available on the TLSI stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own TLSI?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling TLSI. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of TriSalus Life Sciences, Inc.'s investment landscape.